Cargando…
Alzheimer’s Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer’s Clinical Trial Consortium Sites
BACKGROUND: The COVID-19 pandemic created challenges in clinical research operations that required immediate and lasting changes. OJBECTIVES: The purpose of this study was to explore adaptations to clinical trial research due to COVID-19 and develop a theoretical framework of emergent strategies rel...
Autores principales: | Rhodus, Elizabeth K., Aisen, P., Grill, J. D., Rentz, D. M., Petersen, R. C., Sperling, R. A., Salloway, S. P., Pierce, D., Raman, R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9491649/ https://www.ncbi.nlm.nih.gov/pubmed/36281670 http://dx.doi.org/10.14283/jpad.2022.79 |
Ejemplares similares
-
Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial
por: Raman, Rema, et al.
Publicado: (2021) -
The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program
por: Berkness, Tyler, et al.
Publicado: (2021) -
Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD)
por: Walter, S., et al.
Publicado: (2020) -
The Computerized Cognitive Composite (C3) in A4, an Alzheimer’s Disease Secondary Prevention Trial
por: Papp, K.V., et al.
Publicado: (2021) -
Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report
por: Raman, Rema, et al.
Publicado: (2022)